Stay updated with breaking news from Gene Therapy Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF...
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS)
Passage Bio (NASDAQ:PASG – Get Rating) and Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership. Earnings and Valuation This table compares Passage Bio and […]
Relive the Class of 2023's junior year, in which the University transitioned back to in-person life and Liz Magill became the University's ninth president.
- Program Updates Planned for Azer-cel and PBCAR19B in May 2023 - Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT... | May 9, 2023